Navigation Links
Cardica Updates Enrollment Progress In European Clinical Trial
Date:2/27/2013

REDWOOD CITY, Calif., Feb. 27, 2013 /PRNewswire/ -- Cardica, Inc. (Nasdaq: CRDC) today announced that 109 patients have been enrolled in the company's European clinical trial designed to evaluate the safety of its MicroCutter XCHANGE™ 30 cutting/stapling device in a variety of surgical procedures. Cardica plans to complete enrollment of 160 patients for the European clinical trial in the second calendar quarter of 2013.

"We are making progress with the MicroCutter XCHANGE 30 in Europe," said Bernard A. Hausen , M.D., Ph.D., president and chief executive officer of Cardica. "In the last four weeks, we have enrolled an additional 19 patients in our clinical trial, with more scheduled in the days ahead. And, we continue to gain valuable feedback from European surgeons deploying the device in a variety of procedures, to prepare the device for broader distribution in the near future. To date the MicroCutter XCHANGE 30 device has been used in over 280 procedures and deployed more than 800 times."

About Cardica 

Cardica designs and manufactures proprietary stapling and anastomotic devices for cardiac and laparoscopic surgical procedures. Cardica's technology portfolio is intended to minimize operating time and enable minimally-invasive and robot-assisted surgeries. Cardica manufactures and markets its automated anastomosis systems, the C-Port® Distal Anastomosis Systems and PAS-Port® Proximal Anastomosis System for coronary artery bypass graft (CABG) surgery, and has shipped over 44,100 units throughout the world. In addition, Cardica is developing the Cardica® MicroCutter XCHANGE™ 30, a cartridge-based microcutter device with a five-millimeter shaft diameter, and the Cardica® MicroCutter XPRESS™ 30, a true multi-fire laparoscopic stapling device. Both MicroCutter devices are designed to be used in a variety of procedures, including bariatric, colorectal, thoracic and general surgery. The Cardica MicroCutter XCHANGE 30 and XPRESS 30 products require 510(k) review and are not yet commercially available in the U.S. 

Forward-Looking Statements

The statement in this press release regarding Cardica's plans to complete enrollment in the European clinical trial in the second quarter of calendar year 2013,  is a "forward-looking statement." There are a number of important factors that could cause Cardica's results to differ materially from those indicated by this forward-looking statement, including:  that the XCHANGE 30 may face development, regulatory and manufacturing risks; that surgeons may not use the XCHANGE 30 correctly, which could cause unfavorable results that may impair the acceptance of the XCHANGE 30 by other surgeons or otherwise delay completion of enrollment; and that Cardica may not have sufficient funds to complete enrollment in the clinical trial, as well as other risks detailed from time to time in Cardica's reports filed with the U.S. Securities and Exchange Commission, including its Current Report on Form 10-Q for the quarter ended December 31, 2012. Cardica expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein. You are encouraged to read Cardica's reports filed with the U.S. Securities and Exchange Commission, available at www.sec.gov.


'/>"/>
SOURCE Cardica, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardica Announces Fiscal 2012 Third Quarter Financial Results
2. Cardica To Announce Fiscal 2012 Fourth Quarter And Full Year Financial Results On Thursday, August 2, 2012
3. Cardica Announces Fiscal 2012 Fourth Quarter And Year End Financial Results
4. Cardica To Present At 2012 Wedbush PacGrow Life Sciences Management Access Conference
5. Cardica Announces Fiscal 2013 First Quarter Financial Results
6. Cardica To Present At Lazard Capital Markets 9th Annual Healthcare Conference
7. Cardica To Announce Fiscal 2013 Second Quarter Financial Results On Thursday, January 31, 2013
8. Cardica Announces Fiscal 2013 Second Quarter Financial Results
9. Neuralstem Updates ALS Stem Cell Trial Progress
10. Anthera Updates Phase 3 Plans Following Results from the Phase 2b PEARL-SC Dose Ranging Study of Blisibimod
11. TPI Provides Further Updates on its GMOL Flagship Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... , Jan. 24, 2017 The Society ... and the Physician-Patient Alliance for Health & Safety ( ... focused on promoting safety and optimized outcomes for patients ... Gross MD, President of SONORIA and Michael Wong ... serve as advisors to their respective organization,s Boards. ...
(Date:1/24/2017)... , January 24, 2017 www.Financialbuzz.com ... growing industries in the United States ... in 2016. In addition, Proposition 64, the California Cannabis Legalization ... 42.87% against on November 8, 2016. This outcome means that ... use and to grow a certain amount of cannabis for ...
(Date:1/24/2017)... 24, 2017 Mezzion has filed a suit ... court alleging that Dr. Reddy,s committed fraud relating to ... Drug Administration (FDA) cGMP practices, and misrepresenting its compliance ... represented to Mezzion that it was compliant with FDA ... The suit also states that Dr. Reddy,s misconduct was ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 24, 2017 , ... ... and eliminate cyber threats in real-time, today announced a strategic partnership with ... customers to monitor, respond and protect their critical information assets and infrastructure, in ...
(Date:1/24/2017)... ... 24, 2017 , ... His message has been heard by more than 100,000 ... Distracted Driving , Joel Feldman, has reached his biggest national audience yet: the three ... the top newspapers in circulation in the country, and he hopes it will help ...
(Date:1/24/2017)... ... ... Saturday, January 28, the BCFA presents more than 20 local performances including Chinese music, ... Zhou, Mara McClain & Sarah Nordlund Dennis. Local chefs and restaurants provide a taste ... games, crafts & more. Festivities begin at 11:00 am and end at 2:30 pm. ...
(Date:1/24/2017)... ... January 24, 2017 , ... Inspiration, Community ... Well-meaning studies such as the Fordham Institute’s High Stakes for High Achievers ... such as including gifted or high-achieving students as a subgroup and reporting their ...
(Date:1/24/2017)... ... January 24, 2017 , ... Date aired: January ... Sharon Kleyne, the nation’s foremost water advocate and host of the nationally syndicated ... on Voice America, once again welcomed one of her favorite guests and colleagues, ...
Breaking Medicine News(10 mins):